4-year study tracks safety of extended half-life hemophilia drug jivi
NCT ID NCT04461639
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 22 times
Summary
This study follows 62 people with hemophilia A who are already using Jivi (damoctocog alfa pegol) to prevent bleeding. Researchers will collect safety data during routine doctor visits for at least 4 years. The goal is to better understand long-term side effects of this extended half-life Factor VIII medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Many Locations
Multiple Locations, Austria
-
Many Locations
Multiple Locations, Germany
-
Many Locations
Multiple Locations, Greece
-
Many Locations
Multiple Locations, Italy
-
Many Locations
Multiple Locations, Slovenia
-
Many Locations
Multiple Locations, Spain
Conditions
Explore the condition pages connected to this study.